Literature DB >> 28840024

Elucidation of radiation-resistant clones by a serial study of intratumor heterogeneity before and after stereotactic radiotherapy in lung cancer.

Takahiro Nakagomi1, Taichiro Goto1, Yosuke Hirotsu2, Daichi Shikata1, Kenji Amemiya2, Toshio Oyama3, Hitoshi Mochizuki2, Masao Omata2,4.   

Abstract

Stereotactic radiotherapy (SRT) for inoperable stage I non-small cell lung cancer has shown promising results and is now an alternative therapy for this disease. Several reports have detailed changes in mutation profiles after treatment with chemotherapy; however, such changes after SRT for lung cancer have not been reported. A patient who received SRT for lung cancer developed local recurrence 9 months after treatment and underwent surgery in our department. Using bronchoscopically biopsied and surgically resected specimens, we performed targeted sequencing of 53 lung cancer-related genes and compared the tumor mutation profiles before and after SRT. Identical mutations were detected from tumor specimens collected before and after SRT, and the specimens were confirmed to be clonal. However, the number of mutations decreased after SRT, suggesting that it induced mutation selection. Analyses of the statistical inference of clonal population structure showed that this evolving heterogeneous genomic landscape may be caused by heterogeneous responsiveness to SRT.

Entities:  

Keywords:  Stereotactic radiotherapy (SRT); lung cancer; mutation; next-generation sequencing

Year:  2017        PMID: 28840024      PMCID: PMC5542954          DOI: 10.21037/jtd.2017.06.02

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  28 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Authors:  Sashendra Senthi; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Lancet Oncol       Date:  2012-06-22       Impact factor: 41.316

3.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.

Authors:  Yasushi Nagata; Kenji Takayama; Yukinori Matsuo; Yoshiki Norihisa; Takashi Mizowaki; Takashi Sakamoto; Masato Sakamoto; Michihide Mitsumori; Keiko Shibuya; Norio Araki; Shinsuke Yano; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

4.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

5.  Divergent clonal selection dominates medulloblastoma at recurrence.

Authors:  A Sorana Morrissy; Livia Garzia; David J H Shih; Scott Zuyderduyn; Xi Huang; Patryk Skowron; Marc Remke; Florence M G Cavalli; Vijay Ramaswamy; Patricia E Lindsay; Salomeh Jelveh; Laura K Donovan; Xin Wang; Betty Luu; Kory Zayne; Yisu Li; Chelsea Mayoh; Nina Thiessen; Eloi Mercier; Karen L Mungall; Yusanne Ma; Kane Tse; Thomas Zeng; Karey Shumansky; Andrew J L Roth; Sohrab Shah; Hamza Farooq; Noriyuki Kijima; Borja L Holgado; John J Y Lee; Stuart Matan-Lithwick; Jessica Liu; Stephen C Mack; Alex Manno; K A Michealraj; Carolina Nor; John Peacock; Lei Qin; Juri Reimand; Adi Rolider; Yuan Y Thompson; Xiaochong Wu; Trevor Pugh; Adrian Ally; Mikhail Bilenky; Yaron S N Butterfield; Rebecca Carlsen; Young Cheng; Eric Chuah; Richard D Corbett; Noreen Dhalla; An He; Darlene Lee; Haiyan I Li; William Long; Michael Mayo; Patrick Plettner; Jenny Q Qian; Jacqueline E Schein; Angela Tam; Tina Wong; Inanc Birol; Yongjun Zhao; Claudia C Faria; José Pimentel; Sofia Nunes; Tarek Shalaby; Michael Grotzer; Ian F Pollack; Ronald L Hamilton; Xiao-Nan Li; Anne E Bendel; Daniel W Fults; Andrew W Walter; Toshihiro Kumabe; Teiji Tominaga; V Peter Collins; Yoon-Jae Cho; Caitlin Hoffman; David Lyden; Jeffrey H Wisoff; James H Garvin; Duncan S Stearns; Luca Massimi; Ulrich Schüller; Jaroslav Sterba; Karel Zitterbart; Stephanie Puget; Olivier Ayrault; Sandra E Dunn; Daniela P C Tirapelli; Carlos G Carlotti; Helen Wheeler; Andrew R Hallahan; Wendy Ingram; Tobey J MacDonald; Jeffrey J Olson; Erwin G Van Meir; Ji-Yeoun Lee; Kyu-Chang Wang; Seung-Ki Kim; Byung-Kyu Cho; Torsten Pietsch; Gudrun Fleischhack; Stephan Tippelt; Young Shin Ra; Simon Bailey; Janet C Lindsey; Steven C Clifford; Charles G Eberhart; Michael K Cooper; Roger J Packer; Maura Massimino; Maria Luisa Garre; Ute Bartels; Uri Tabori; Cynthia E Hawkins; Peter Dirks; Eric Bouffet; James T Rutka; Robert J Wechsler-Reya; William A Weiss; Lara S Collier; Adam J Dupuy; Andrey Korshunov; David T W Jones; Marcel Kool; Paul A Northcott; Stefan M Pfister; David A Largaespada; Andrew J Mungall; Richard A Moore; Nada Jabado; Gary D Bader; Steven J M Jones; David Malkin; Marco A Marra; Michael D Taylor
Journal:  Nature       Date:  2016-01-13       Impact factor: 49.962

Review 6.  Evolving concepts of tumor heterogeneity.

Authors:  Victoria R Zellmer; Siyuan Zhang
Journal:  Cell Biosci       Date:  2014-11-25       Impact factor: 7.133

Review 7.  Targeting Notch to overcome radiation resistance.

Authors:  Sanaz Yahyanejad; Jan Theys; Marc Vooijs
Journal:  Oncotarget       Date:  2016-02-16

8.  High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.

Authors:  Sing-Huang Tan; Nur Sabrina Sapari; Hui Miao; Mikael Hartman; Marie Loh; Wee-Joo Chng; Philip Iau; Shaik Ahmad Buhari; Richie Soong; Soo-Chin Lee
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

9.  OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action.

Authors:  Michael P Schroeder; Carlota Rubio-Perez; David Tamborero; Abel Gonzalez-Perez; Nuria Lopez-Bigas
Journal:  Bioinformatics       Date:  2014-09-01       Impact factor: 6.937

10.  Increased Notch Signaling Enhances Radioresistance of Malignant Stromal Cells Induced by Glioma Stem/ Progenitor Cells.

Authors:  Yuntian Shen; Hua Chen; Jinshi Zhang; Yanming Chen; Mengyao Wang; Jiawei Ma; Lei Hong; Ning Liu; Qiuhong Fan; Xueguan Lu; Ye Tian; Aidong Wang; Jun Dong; Qing Lan; Qiang Huang
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more
  3 in total

1.  Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3.

Authors:  Takahiro Nakagomi; Taichiro Goto; Yosuke Hirotsu; Daichi Shikata; Yujiro Yokoyama; Rumi Higuchi; Sotaro Otake; Kenji Amemiya; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  Cancers (Basel)       Date:  2018-11-30       Impact factor: 6.639

2.  Primary Driver Mutations in GTF2I Specific to the Development of Thymomas.

Authors:  Rumi Higuchi; Taichiro Goto; Yosuke Hirotsu; Yujiro Yokoyama; Takahiro Nakagomi; Sotaro Otake; Kenji Amemiya; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639

3.  The Diagnostic Utility of Cell-Free DNA from Ex Vivo Bronchoalveolar Lavage Fluid in Lung Cancer.

Authors:  Sotaro Otake; Taichiro Goto; Rumi Higuchi; Takahiro Nakagomi; Yosuke Hirotsu; Kenji Amemiya; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.